Cargando…
Autochthonous T cells to the rescue: IL-10 directly activates tumor-resident CD8(+) T cells
Successful cancer immunotherapy is thought to require de novo priming of tumor specific CD8(+) T cells in lymphatic organs. Contrasting these beliefs, cancer therapy based on interleukin-10 (IL-10) results in tumor rejection without a requirement for T-cell trafficking from lymphatic organs. Rather,...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Landes Bioscience
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3525629/ https://www.ncbi.nlm.nih.gov/pubmed/23264920 http://dx.doi.org/10.4161/onci.21683 |